Part 3: Myelodysplastic syndromes-Treatment of low-risk patients without the 5q deletion.

Hematol Transfus Cell Ther · 2018 · PMC6098188 · PMID 30128437

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

However, a meta-analysis of eight observational studies with different types of chelators involving 1562 participants (median participants per study: 153; range: 78–534) showed a trend toward longer OS in patients who took chelators particularly those with LR-MDS.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.